Omniasecure, which was authorized for placement in the heart’s right ventricle, is the world’s smallest defibrillation lead, ...

Patients awaiting a heart transplant are often implanted with an ... and funding for pediatric heart devices. The network is working with the U.S. Food and Drug Administration (FDA) to expand ...

The US Food & Drug Administration has approved EBR System’s leadless pacemaker WISE, the only device able to deliver left-ventricle stimulation. Don't miss out on the headlines from Stockhead.

Medtronic (NYSE: MDT) announced that it received FDA approval for its OmniaSecure defibrillation lead for right ventricle placement.

Carmat is preparing to commence implants ... tumour. "FDA conditionally approves second cohort of Carmat’s artificial heart study" was originally created and published by Medical Device Network ...

Inspectors found ICU Medical made multiple changes to infusion pumps without submitting premarket notifications.

EBR Systems, the heart device hopeful heavily backed by high-profile ... begin selling its technology within months. The Food and Drug Administration approval means the company can begin ...

The US Food & Drug Administration has approved EBR System’s leadless pacemaker WISE, the only device able to deliver left-ventricle stimulation. Ecstatic CEO John McCutcheon said the FDA's ...

Abbott Laboratories has announced that its implantable heart device, MitraClip, has not been recommended for approval by reviewers at the US Food and Drug Administration. Clinical trials ...

Echt saw a problem with leads and thought there was a better way to defibrillate (reduce dangerous rapid heartbeat) the heart. With a background in sales and marketing in the heart device sector ...

The FDA has approved EBR’s WISE device, the world’s only leadless pacemaker for left-ventricle stimulation The company will undergo a cautious staged rollout in the US$3.6 billion-a-year US ...